These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35491518)

  • 1. Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity.
    Stensen S; Krogh LL; Sparre-Ulrich AH; Dela F; Hartmann B; Vilsbøll T; Holst JJ; Rosenkilde MM; Christensen MB; Gasbjerg LS; Knop FK
    Diabetes Obes Metab; 2022 Sep; 24(9):1882-1887. PubMed ID: 35491518
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
    Bergmann NC; Lund A; Gasbjerg LS; Meessen ECE; Andersen MM; Bergmann S; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Knop FK
    Diabetologia; 2019 Apr; 62(4):665-675. PubMed ID: 30683945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.
    Bergmann NC; Gasbjerg LS; Heimbürger SM; Krogh LSL; Dela F; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Lund A; Knop FK
    Diabetes Care; 2020 Mar; 43(3):588-596. PubMed ID: 31949084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
    Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
    Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
    Campbell JE
    Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-mediated control of cardiac energy metabolism.
    Chan JSF; Shafaati T; Ussher JR
    J Endocrinol; 2024 Oct; 263(1):. PubMed ID: 39013412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review.
    Mathiesen DS; Bagger JI; Bergmann NC; Lund A; Christensen MB; Vilsbøll T; Knop FK
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.
    Holst JJ; Rosenkilde MM
    J Clin Endocrinol Metab; 2020 Aug; 105(8):e2710-6. PubMed ID: 32459834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes.
    Bailey CJ; Flatt PR
    Peptides; 2024 Apr; 174():171168. PubMed ID: 38320643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
    Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate release of substance P from TRPV1- and TRPA1-expressing sensory nerves.
    Mayer F; Gunawan AL; Tso P; Aponte GW
    Am J Physiol Gastrointest Liver Physiol; 2020 Jul; 319(1):G23-G35. PubMed ID: 32421358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incretin/glucagon system as a target for pharmacotherapy of obesity.
    Del Prato S; Gallwitz B; Holst JJ; Meier JJ
    Obes Rev; 2022 Feb; 23(2):e13372. PubMed ID: 34713962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
    Thondam SK; Cuthbertson DJ; Wilding JPH
    Peptides; 2020 Mar; 125():170208. PubMed ID: 31759125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
    Tan Q; Akindehin SE; Orsso CE; Waldner RC; DiMarchi RD; Müller TD; Haqq AM
    Front Endocrinol (Lausanne); 2022; 13():838410. PubMed ID: 35299971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.